To investigate tumour evolution in response to therapy we tracked driver mutations (APC, TP53, KRAS, PIK3CA, BRAF) in tumours with pre- and on-NACRT samples (Figures S2 and S3). This evidence concerns the gene KRAS and neoplasm.